Abstract | BACKGROUND AND AIMS: METHODS: MI patients treated with durable- polymer second-generation DES from two randomized trials, SMART-DATE and DAPT- STEMI, were pooled. The primary endpoint was a composite of net adverse clinical events (NACEs) defined by all-cause mortality, any MI, stroke and BARC 3-5 bleeding, between 6 and 18 months after index percutaneous coronary intervention. RESULTS: A total of 2016 patients were analyzed, 1014 were treated with 6-month DAPT versus 1002 patients with ≥12-month DAPT duration. The primary endpoint occurred in 2.7% vs 2.5% (HR 1.07; 95%CI 0.62-1.85, p = 0.80) of cases, in 6 vs ≥ 12-month DAPT, respectively. The composite of cardiac death, MI and stroke was similar (2% vs 1.6%, HR 1.24, 95%CI 0.65-2.4, p = 0.52). BARC 3-5 bleeding occurred more frequently in the ≥12-month DAPT (0.2% vs 0.9%, HR 0.22, 95%CI 0.05-1.02 p = 0.05, log rank p = 0.03). MI occurred more frequently in the 6-month DAPT (1.6% vs 0.6%, HR 2.66, 95%CI 1.04-6.79, p = 0.04). Stent thrombosis was similar in both arms (0.7% vs 0.5%, p = 0.26). CONCLUSIONS: Six vs ≥ 12-month DAPT, followed by aspirin alone, resulted in comparable NACEs in patients with event-free MI at six months after durable- polymer DES implantation. However, single therapy with aspirin beyond the 6 months reduced bleeding rates but was associated with a higher rate of MI compared to ≥12-month DAPT.
|
Authors | Elvin Kedhi, Ronak Delewi, Enrico Fabris, Giuseppe De Luca, Renicus S Hermanides, Martin van den Ent, Pawel Buszman, Felix Zijlstra, Young Bin Song, Hyeon-Cheol Gwon, Joo-Yong Hahn |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 315
Pg. 55-61
(12 2020)
ISSN: 1879-1484 [Electronic] Ireland |
PMID | 33227548
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier B.V. All rights reserved. |
Chemical References |
- Platelet Aggregation Inhibitors
|
Topics |
- Drug Therapy, Combination
- Drug-Eluting Stents
- Humans
- Myocardial Infarction
(diagnosis, drug therapy)
- Percutaneous Coronary Intervention
(adverse effects)
- Platelet Aggregation Inhibitors
(adverse effects)
- ST Elevation Myocardial Infarction
(drug therapy)
- Treatment Outcome
|